The risk of recurrence and death was significantly reduced by concurrent treatment with cisplatin and radiotherapy .
This difference appearedd to be due to the lower rate of relapses in the pelvic region in the combine-therapy group .
ALthough this regimen was also associated with higher rates of adverse effects ,  these effects consisted predominantly of transient hematologic and gastrointestinal effects ,  with no evidence of an increase in other serious effects .
There was no evidence of a difference in the frequencies of late adverse effects between the groups .
